Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Items 201–400 of 695
Castanheira, M., Rhomberg, P. R., Flamm, R. K., & Jones, R. N. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00711-16 · Cited by 135
Class C β-Lactamases: Molecular Characteristics
Philippon, A., Arlet, G., Labia, R., & Iorga, B. I. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00150-21 · Cited by 135
FDA adds "black box" warning label to fluoroquinolone antibiotics
Tanne, J. H. (2008) · BMJ · doi:10.1136/bmj.a816 · Cited by 133
Jung, S. Y., Lee, S. H., Lee, S., Yang, S., Noh, H., Chung, E. K., & Lee, J. I. (2017) · Critical Care · doi:10.1186/s13054-017-1916-6 · Cited by 133
Gaibani, P., Giani, T., Bovo, F., Lombardo, D., Amadesi, S., Lazzarotto, T., Coppi, M., Rossolini, G. M., & Ambretti, S. (2022) · Antibiotics · doi:10.3390/antibiotics11050628 · Cited by 132
Wang, Y. L., Scipione, M. R., Dubrovskaya, Y., & Papadopoulos, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-13 · Cited by 130
Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations
Papp‐Wallace, K. M., Mack, A. R., Taracila, M. A., & Bonomo, R. A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.001 · Cited by 130
Self-citationBetrosian, A. P., Frantzeskaki, F., Xanthaki, A., & Georgiadis, G. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540600951184 · Cited by 129
Lahiri, S. D., Walkup, G. K., Whiteaker, J. D., Palmer, T., McCormack, K., Tanudra, M. A., Nash, T. J., Thresher, J., Johnstone, M. R., Hajec, L., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv004 · Cited by 129
Matsumura, Y., Yamamoto, M., Nagao, M., Komori, T., Fujita, N., Hayashi, A., Shimizu, T., Watanabe, H., Doi, S., Tanaka, M., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-15 · Cited by 129
Sader, H. S., Castanheira, M., Flamm, R. K., Farrell, D. J., & Jones, R. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02429-13 · Cited by 129
Popejoy, M. W., Paterson, D. L., Cloutier, D. J., Huntington, J. A., Miller, B. W., Bliss, C. A., Steenbergen, J. N., Hershberger, E., Umeh, O., & Kaye, K. S. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw374 · Cited by 129
Zha, L., Pan, L., Guo, J., French, N., Villanueva, E., & Tefsen, B. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01235-y · Cited by 129
Ni, W., Han, Y., Liu, J., Wei, C., Zhao, J., Cui, J., Wang, R., & Liu, Y.-N. (2016) · Medicine · doi:10.1097/md.0000000000003126 · Cited by 127
Karlowsky, J. A., Biedenbach, D. J., Kazmierczak, K. M., Stone, G. G., & Sahm, D. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02286-15 · Cited by 126
Dickstein, Y., Lellouche, J., Dalak, M. A. B., Schwartz, D. A., Nutman, A., Daitch, V., Yahav, D., Leibovici, L., Skiada, A., Antoniadou, A., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy988 · Cited by 125
Karlowsky, J. A., Hackel, M., McLeod, S. M., & Miller, A. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00781-22 · Cited by 125
Charrel, R. N., Pagès, J. M., De Micco, P., & Mallea, M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2854 · Cited by 124
Grillon, A., Schramm, F., Kleinberg, M., & Jehl, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156690 · Cited by 124
Livermore, D. M., Day, M. J., Cleary, P. R., Hopkins, K. L., Toleman, M. A., Wareham, D. W., Wiuff, C., Doumith, M., & Woodford, N. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky453 · Cited by 124
Presence of Tetracycline Resistance Determinants and Susceptibility to Tigecycline and Minocycline
Fluit, A. C., Florijn, A., Verhoef, J., & Milatović, D. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1636-1638.2005 · Cited by 122
Falagas, M. E., Skalidis, T., Vardakas, K. Z., Legakis, N. J., & on behalf of the Hellenic Cefiderocol Study Group (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx049 · Cited by 122
Burkhardt, O., Kumar, V., Katterwe, D., Majcher-Peszynska, J., Drewelow, B., Derendorf, H., & Welte, T. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl485 · Cited by 121
Simner, P. J., Mostafa, H. H., Bergman, Y., Ante, M., Tekle, T., Adebayo, A., Beisken, S., Dzintars, K., & Tamma, P. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab888 · Cited by 121
Self-citationTimsit, J., Paul, M., Shields, R. K., ECHOLS, R. M., Baba, T., Yamano, Y., & Portsmouth, S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac078 · Cited by 121
Sader, H. S., Castanheira, M., Shortridge, D., Mendes, R. E., & Flamm, R. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01045-17 · Cited by 120
Kohlmann, R., Bähr, T., & Gatermann, S. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky084 · Cited by 120
Papp‐Wallace, K. M., Bethel, C. R., Caillon, J., Barnes, M. D., Potel, G., Bajaksouzian, S., Rutter, J. D., Reghal, A., Shapiro, S., Taracila, M. A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00105-19 · Cited by 120
Self-citationFreire, M. P., Garcia, D. D. O., Garcia, C. P., Bueno, M. F. C., Camargo, C. H., Magri, A. S. G. K., Francisco, G. R., da Silva, R. R., Vieira, M. F., Ibrahim, K. Y., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.12.010 · Cited by 119
Nakamura, R., Ito-Horiyama, T., Takemura, M., Toba, S., Matsumoto, S., Ikehara, T., Tsuji, M., Sato, T., & Yamano, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02031-18 · Cited by 119
Accurate Identification of Clinically Important Acinetobacter Spp.: An Update
Vijayakumar, S., Biswas, I., & Veeraraghavan, B. (2019) · Future Science OA · doi:10.2144/fsoa-2018-0127 · Cited by 119
Mushtaq, S., Sadouki, Z., Vickers, A. A., Livermore, D. M., & Woodford, N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01582-20 · Cited by 119
Ko, J., Kang, C., Cornejo‐Juárez, P., Yeh, K., Wang, C.-H., Cho, S. Y., Gözel, M. G., Kim, S., Hsueh, P., Sekiya, N., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.11.008 · Cited by 118
Goodlet, K. J., Benhalima, F. Z., & Nailor, M. D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02165-18 · Cited by 116
IRT and CMT β-lactamases and inhibitor resistance
Cantón, R., Morosini, M.-I., Martin, O., de la Maza, S., & de la Pedrosa, E. G. G. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01849.x · Cited by 115
Walkty, A., Adam, H., Baxter, M., Denisuik, A., Lagacé-Wiens, P., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02744-13 · Cited by 115
Chopra, T., Marchaim, D., Veltman, J., Johnson, P., Zhao, J. J., Tansek, R., Hatahet, D., Chaudhry, K., Pogue, J. M., Hiro, R., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05419-11 · Cited by 115
Seo, Y. B., Lee, J., Kim, Y. K., Lee, S. S., Lee, J.-A., Kim, H. Y., Uh, Y., Kim, H.-S., & Song, W. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2502-x · Cited by 115
Lee, C.-H., Su, L.-H., Tang, Y., & Liu, J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl381 · Cited by 114
LUCASTI, C. J., Hershberger, E., Miller, B. W., Yankelev, S., Steenbergen, J. N., Friedland, I. R., & Solomkin, J. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00049-14 · Cited by 114
Zhang, Y., Kashikar, A., Brown, C. A., Denys, G. A., & Bush, K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00389-17 · Cited by 113
Is Fosfomycin a Potential Treatment Alternative for Multidrug-Resistant Gram-Negative Prostatitis?
Gardiner, B. J., Mahony, A. A., Ellis, A. G., Lawrentschuk, N., Bolton, D. M., Zeglinski, P. T., Frauman, A. G., & Grayson, M. L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit704 · Cited by 112
Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2
Hemarajata, P., & Humphries, R. M. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz026 · Cited by 112
Farrell, D. J., Sader, H. S., & Jones, R. N. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01774-09 · Cited by 111
Wang, Q., Jin, L., Sun, S., Yin, Y., Wang, R., Chen, F., Wang, X., Zhang, Y., Hou, J., Zhang, Y., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02670-21 · Cited by 111
Kuo, L.-C., Lai, C., Liao, C., Hsu, C.-K., Chang, Y.-L., Chang, C.-Y., & Hsueh, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01601.x · Cited by 110
Molecular basis of beta-lactamase induction in bacteria
Bennett, P. M., & Chopra, I. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.153 · Cited by 109
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
Maselli, D. J., Keyt, H., & Restrepo, M. I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051062 · Cited by 109
Synergistic combinations of polymyxins
Lenhard, J. R., Nation, R. L., & Tsuji, B. T. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.09.014 · Cited by 108
Seifert, H., Stefanik, D., Sutcliffe, J. A., & Higgins, P. G. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.022 · Cited by 108
Jacobs, M. R., Abdelhamed, A. M., Good, C. E., Rhoads, D. D., Hujer, K. M., Hujer, A. M., Domitrovic, T. N., Rudin, S. D., Richter, S. S., van Duin, D., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01801-18 · Cited by 108
Self-citationHsueh, S.-C., Lee, Y., Huang, Y., Liao, C., Tsuji, M., & Hsueh, P. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky425 · Cited by 108
Papp‐Wallace, K. M., Barnes, M. D., Alsop, J., Taracila, M. A., Bethel, C. R., Becka, S. A., van Duin, D., Kreiswirth, B. N., Kaye, K. S., & Bonomo, R. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00174-18 · Cited by 107
Self-citationTigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens
Poulakou, G., Kontopidou, F. V., Paramythiotou, E., Kompoti, M., Katsiari, M., Mainas, E., Nicolaou, C., Yphantis, D., Antoniadou, A., Trikka‐Graphakos, E., et al. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.02.009 · Cited by 106
Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint
Burkhardt, O., Rauch, K., Kaever, V., Hadem, J., Kielstein, J. T., & Welte, T. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.015 · Cited by 106
Shields, R. K., McCreary, E. K., Marini, R. V., Kline, E. G., Jones, C. E., Hao, B., Chen, L., Kreiswirth, B. N., Doi, Y., Clancy, C. J., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1131 · Cited by 106
Self-citationHancock, R. E. W., & Bellido, F. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/29.suppl_a.1 · Cited by 105
Cho, S. Y., Kang, C., Kim, J., Ha, Y. E., Chung, D. R., Lee, N. Y., Peck, K. R., & Song, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01682-13 · Cited by 105
Biagi, M. J., Wu, T., Lee, M., Patel, S., Butler, D. A., & Wenzler, E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01426-19 · Cited by 105
Cheng, L., Nelson, B. C., Mehta, M., Seval, N., Park, S. E., Giddins, M. J., Shi, Q., Whittier, S., Gomez‐Simmonds, A., & Uhlemann, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00276-17 · Cited by 104
Petrosillo, N., Giannella, M., Antonelli, M. M., Antonini, M., Baršić, B., Belancic, L., İnkaya, A. Ç., PASCALE, G. D., Grilli, E., Tumbarello, M., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00871-13 · Cited by 103
Heil, E. L., Bork, J. T., Abbo, L. M., Barlam, T. F., Cosgrove, S. E., Davis, A. E., Ha, D. R., Jenkins, T. C., Kaye, K. S., Lewis, J. S., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab434 · Cited by 103
Self-citationLopez-Cortes, L. E., Cisneros, J. M., Fernandez-Cuenca, F., Bou, G., Tomas, M., Garnacho-Montero, J., Pascual, A., Martinez-Martinez, L., Vila, J., Pachon, J., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku233 · Cited by 102
Kalın, G., Alp, E., Demiraslan, H., Doğanay, M., Coskun, R., & Gündoğan, K. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0430-7 · Cited by 101
Aerosolized Antibiotics for Ventilator-associated Pneumonia: Lessons from Experimental Studies
Rouby, J., Bouhemad, B., Monsel, A., Brisson, H., Arbelot, C., & Lü, Q. (2012) · Anesthesiology · doi:10.1097/aln.0b013e3182755d7a · Cited by 101
Activity of Ertapenem (MK-0826) versus Enterobacteriaceae with Potent β-Lactamases
Livermore, D. M., Oakton, K. J., Carter, M. W., & Warner, M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2831-2837.2001 · Cited by 101
Compain, F., & Arthur, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00451-17 · Cited by 101
Karaiskos, I., Daikos, G. L., Gkoufa, A., Adamis, G., Stefos, A., Symbardi, S., Chrysos, G., Filiou, E., Basoulis, D., Mouloudi, E. K., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa503 · Cited by 101
Krizova, L., Poirel, L., Nordmann, P., & Nemec, A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt275 · Cited by 100
Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity
de Oliveira, M. S., do Prado, G. V. B., Costa, S. F., Grinbaum, R. S., & Levin, A. S. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.07.018 · Cited by 99
Mojica, M. F., Rutter, J. D., Taracila, M. A., Abriata, L. A., Fouts, D. E., Papp‐Wallace, K. M., Walsh, T. J., LiPuma, J. J., Vila, A. J., & Bonomo, R. A. (2019) · mBio · doi:10.1128/mbio.00405-19 · Cited by 99
Self-citationShields, R. K., Iovleva, A., Kline, E. G., Kawai, A., McElheny, C. L., & Doi, Y. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa355 · Cited by 99
Gill, C. M., Aktaþ, E., Alfouzan, W. A., Bourassa, L. A., Brink, A. J., Burnham, C. D., Cantón, R., Carmeli, Y., Falcone, M., Kiffer, C. R. V., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04308-0 · Cited by 99
Chen, M., Nafziger, A. N., Drusano, G. L., Ma, L., & Bertino, J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1222-1227.2006 · Cited by 98
Makris, D. A., Petinaki, E., Tsolaki, V., Manoulakas, E., Mantzarlis, K. D., Apostolopoulou, O., Sfyras, D., & Zakynthinos, E. G. (2018) · Indian Journal of Critical Care Medicine · doi:10.4103/ijccm.ijccm_302_17 · Cited by 98
Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo
Göttig, S., Frank, D., Mungo, E., Nolte, A., Hogardt, M., Besier, S. M., & Wichelhaus, T. A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz330 · Cited by 98
Stewart, A. G., Paterson, D. L., Young, B. E., Lye, D. C., Davis, J. S., Schneider, K., Yılmaz, M., Dinleyici, R., Runnegar, N. J., Henderson, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab387 · Cited by 98
Falagas, M. E., Vardakas, K. Z., Tsiveriotis, K., Triarides, N. A., & Tansarli, G. S. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.006 · Cited by 97
Kalın, G., Alp, E., Akin, A., Coskun, R., & Doğanay, M. (2013) · Infection · doi:10.1007/s15010-013-0495-y · Cited by 97
Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia
Siedner, M. J., Galar, A., Guzmán‐Suarez, B. B., Kubiak, D. W., Baghdady, N., Ferraro, M. J., Hooper, D. C., O’Brien, T. F., & Marty, F. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu182 · Cited by 97
Pfaller, M. A., Bassetti, M., Duncan, L. R., & Castanheira, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx009 · Cited by 97
Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.
Al-Jasser, A. M. (2006) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-5-23 · Cited by 96
Pfaller, M. A., Huband, M. D., Mendes, R. E., Flamm, R. K., & Castanheira, M. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.02.021 · Cited by 96
Falagas, M. E., Kasiakou, S. K., Kofteridis, D. P., Roditakis, G., & Samonis, G. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0191-2 · Cited by 95
Morris, C. P., Bergman, Y., Tekle, T., Fissel, J. A., Tamma, P. D., & Simner, P. J. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01649-20 · Cited by 95
Self-citationA Review of Intravenous Minocycline for Treatment of Multidrug-Resistant Acinetobacter Infections
Ritchie, D. J., & Garavaglia-Wilson, A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu613 · Cited by 94
Khan, A., Erickson, S. G., Pettaway, C. H., Arias, C. A., Miller, W. R., & Bhatti, M. M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00846-21 · Cited by 94
Wood, G. C., Hanes, S. D., Boucher, B. A., Croce, M. A., & Fabian, T. C. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-1811-2 · Cited by 93
Aph(3′)-IIc, an Aminoglycoside Resistance Determinant from Stenotrophomonas maltophilia
Okazaki, A., & Avison, M. B. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00795-06 · Cited by 92
Harris, P. N. A., Wei, J. Y., Shen, A., Abdile, A. A., Paynter, S., Huxley, R., Pandeya, N., Doi, Y., Huh, K., O’Neal, C. S., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv346 · Cited by 92
Liang, C.-A., Lin, Y.-C., Lu, P., Chen, H.-C., Chang, H.-M., & Sheu, C. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.10.033 · Cited by 92
Castanheira, M., Davis, A. P., Mendes, R. E., Serio, A. W., Krause, K. M., & Flamm, R. K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00313-18 · Cited by 92
Bostanghadiri, N., Ghalavand, Z., Fallah, F., Yadegar, A., Ardebili, A., Tarashi, S., Pournajaf, A., Mardaneh, J., Shams, S., & Hashemi, A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01191 · Cited by 92
McLeod, S. M., Moussa, S. H., Hackel, M., & Miller, A. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02534-19 · Cited by 92
Ofer-Friedman, H., Shefler, C., Sharma, S., Tirosh, A., Tal-Jasper, R., Kandipalli, D., Sharma, S., Bathina, P., Kaplansky, T., Maskit, M., et al. (2015) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2015.101 · Cited by 91
Araoka, H., Baba, M., & Yoneyama, A. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-0882-6 · Cited by 90
Robberts, F. J. L., Kohner, P. C., & Patel, R. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01687-08 · Cited by 89
Zelenitsky, S. A., Iacovides, H., Ariano, R. E., & Harding, G. K. M. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.09.002 · Cited by 89
Sader, H. S., Castanheira, M., Flamm, R. K., Mendes, R. E., Farrell, D. J., & Jones, R. N. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.02.022 · Cited by 89
Griffith, D. C., Sabet, M., Tarazi, Z., Lomovskaya, O., & Dudley, M. N. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01659-18 · Cited by 89
Gaibani, P., Re, M. C., Campoli, C., Viale, P., & Ambretti, S. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.011 · Cited by 89
López-Rojas, R., McConnell, M. J., Me, J.-M., Domínguez-Herrera, J., Fernández-Cuenca, F., & Pachón, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-13 · Cited by 88
Kim, W., Moon, J.-Y., Huh, J. W., Choi, S., Lim, C., Koh, Y., Chong, Y. P., & Hong, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150642 · Cited by 88
Lenhard, J. R., Smith, N. M., Bulman, Z. P., Tao, X., Thamlikitkul, V., Shin, B. S., Nation, R. L., Li, J., Bulitta, J. B., & Tsuji, B. T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01268-16 · Cited by 88
MacVane, S. H., Pandey, R., Steed, L. L., Kreiswirth, B. N., & Chen, L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01183-17 · Cited by 88
Athans, V., Neuner, E. A., Hassouna, H., Richter, S. S., Keller, G., Castanheira, M., Brizendine, K. D., & Mathers, A. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01551-18 · Cited by 88
Self-citationOXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
Fröhlich, C., Sørum, V., Thomassen, A. M., Johnsen, P. J., Leiros, H. S., & Samuelsen, Ø. (2019) · mSphere · doi:10.1128/msphere.00024-19 · Cited by 88
Sader, H. S., Mendes, R. E., Pfaller, M. A., Shortridge, D., Flamm, R. K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01856-17 · Cited by 87
Butler, D. A., Biagi, M. J., Tan, X., Qasmieh, S., Bulman, Z. P., & Wenzler, E. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0706-5 · Cited by 87
Fraile-Ribot, P. A., Zamorano, L., Orellana, R., del Barrio-Tofiño, E., Sánchez-Diener, I., Cortés-Lara, S., López-Causapé, C., Cabot, G., Bou, G., Martı́nez-Martı́nez, L., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02165-19 · Cited by 87
Kawai, A., McElheny, C. L., Iovleva, A., Kline, E. G., Sluis‐Cremer, N., Shields, R. K., & Doi, Y. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00198-20 · Cited by 87
Shortridge, D., Castanheira, M., Pfaller, M. A., & Flamm, R. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00465-17 · Cited by 86
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Hawser, S., Magnet, S., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky107 · Cited by 86
Sader, H. S., Castanheira, M., Mendes, R. E., & Flamm, R. K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky279 · Cited by 86
Harada, Y., Morinaga, Y., Kaku, N., Nakamura, S., Uno, N., Hasegawa, H., Izumikawa, K., KOHNO, S., & Yanagihara, K. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12677 · Cited by 85
Chan, J. D., Graves, J. A., & Dellit, T. H. (2010) · Journal of Intensive Care Medicine · doi:10.1177/0885066610377975 · Cited by 85
Castanheira, M., Mendes, R. E., & Jones, R. N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu706 · Cited by 85
Wilson, W. R., Kline, E. G., Jones, C. E., Morder, K. M., Mettus, R. T., Doi, Y., Nguyen, M. H., Clancy, C. J., & Shields, R. K. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02048-18 · Cited by 85
Self-citationLodise, T. P., Smith, N. M., O’Donnell, J. N., Eakin, A. E., Holden, P. N., Boissonneault, K. R., Zhou, J., Tao, X., Bulitta, J. B., Fowler, V. G., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa197 · Cited by 85
Self-citationEckmann, C., Montravers, P., Bassetti, M., Bodmann, K. ‐., Heizmann, W. R., García, M. S., Guirao, X., Capparella, M. R., Simoneau, D., & Dupont, H. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt142 · Cited by 84
Wei, C., Ni, W., Cai, X., Zhao, J., & Cui, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152132 · Cited by 84
Sader, H. S., Castanheira, M., Mendes, R. E., Flamm, R. K., Farrell, D. J., & Jones, R. N. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05024-14 · Cited by 83
Hooton, T. M., Roberts, P. L., & Stapleton, A. E. (2012) · JAMA · doi:10.1001/jama.2012.80 · Cited by 83
Lee, N., Lee, C., Li, C., Li, M.-C., Chen, P., Chang, C., & Ko, W. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01477-15 · Cited by 83
la Calle, C. D., Rodríguez-Núñez, O., Morata, L., Marco, F., Cardozo, C., García‐Vidal, C., del Río, A., Fehér, C., Pellicé, M., Puerta‐Alcalde, P., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.015 · Cited by 83
Punjabi, C. D., Tien, V., Meng, L., Deresinski, S. C., & Holubar, M. K. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz364 · Cited by 83
Alraddadi, B. M., Saeedi, M. F., Qutub, M., Alshukairi, A. N., Hassanien, A., & Wali, G. Y. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4409-1 · Cited by 82
Seifert, H., Müller, C., Stefanik, D., Higgins, P. G., Miller, A. A., & Kresken, M. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa208 · Cited by 82
Kawaguchi, N., Katsube, T., ECHOLS, R. M., & Wajima, T. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01437-20 · Cited by 82
Reddy, T., Chopra, T., Marchaim, D., Pogue, J. M., Alangaden, G. J., Salimnia, H., Boikov, D. A., Navon‐Venezia, S., Akins, R. A., Selman, P., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01665-09 · Cited by 81
Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
Fukuchi, T., Iwata, K., Kobayashi, S., Nakamura, T., & Ohji, G. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1770-1 · Cited by 81
Mojica, M. F., Papp‐Wallace, K. M., Taracila, M. A., Barnes, M. D., Rutter, J. D., Jacobs, M. R., LiPuma, J. J., Walsh, T. J., Vila, A. J., & Bonomo, R. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00777-17 · Cited by 81
Self-citationKazakova, S. V., Baggs, J. M., McDonald, L. C., Yi, S. H., Hatfield, K. M., Guh, A. Y., Reddy, S. C., & Jernigan, J. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz169 · Cited by 81
Simner, P. J., Beisken, S., Bergman, Y., Posch, A. E., Cosgrove, S. E., & Tamma, P. D. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab311 · Cited by 81
Self-citationBurgess, D. S., & Hall, R. G. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.11.007 · Cited by 80
Doi, A., Shimada, T., Harada, S., Iwata, K., & Kamiya, T. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.09.010 · Cited by 80
Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis
Brink, A. J., Richards, G., Schillack, V., Kiem, S., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.005 · Cited by 80
ALLEN, J. C. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-85-4-482 · Cited by 80
Mojica, M. F., Ouellette, C. P., Leber, A. L., Becknell, B., Ardura, M. I., Pérez, F., Shimamura, M., Bonomo, R. A., Aitken, S. L., & Shelburne, S. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00264-16 · Cited by 80
Self-citationSpiliopoulou, I. T., Kazmierczak, K. M., & Stone, G. G. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz456 · Cited by 80
Hakeam, H. A., Al-Sahli, H., Albabtain, L., Alassaf, S., Duhailib, Z. A., & Althawadi, S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.079 · Cited by 80
Findlay, J., Poirel, L., Bouvier, M., & Nordmann, P. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.05.011 · Cited by 79
Senchyna, F., Gaur, R. L., Sandlund, J., Truong, C., Tremintin, G., Kültz, D., Gómez, C. A., Tamburini, F. B., Andermann, T. M., Bhatt, A. S., et al. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.10.004 · Cited by 78
Streling, A. P., Al‐Obaidi, M. M., Lainhart, W., Zangeneh, T. T., Khan, A., Dinh, A. Q., Hanson, B., Arias, C. A., & Miller, W. R. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1909 · Cited by 78
Diverse potential of beta-lactamase inhibitors to induce class I enzymes
Weber, D. A., & Sanders, C. C. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.156 · Cited by 77
Hand, E., Davis, H., Kim, T., & Duhon, B. M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv456 · Cited by 77
Stone, G. G., Newell, P., Gasink, L. B., Broadhurst, H., Wardman, A., Yates, K., Chen, Z., Song, J., & Chow, J. W. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky204 · Cited by 77
Assessment of Minocycline and Polymyxin B Combination against Acinetobacter baumannii
Bowers, D. R., Cao, H., Zhou, J. M., Ledesma, K. R., Sun, D., Lomovskaya, O., & Tam, V. H. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04110-14 · Cited by 76
Cañestro, M. D., Periañez, L., Mulet, X., Martín-Pena, M. L., Fraile-Ribot, P. A., Ayestarán, I., Colomar, A., Núñez, B., Macia, M. D., Novo, A., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3361-0 · Cited by 76
Doshi, N., Cook, C. H., Mount, K. L., Stawicki, S. P., Frazee, E. N., Personett, H. A., Schramm, G. E., Arnold, H. M., & Murphy, C. V. (2013) · BMC Anesthesiology · doi:10.1186/1471-2253-13-45 · Cited by 75
Castanheira, M., Deshpande, L. M., Woosley, L. N., Serio, A. W., Krause, K. M., & Flamm, R. K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky344 · Cited by 75
Castanheira, M., Doyle, T. B., Collingsworth, T. D., Sader, H. S., & Mendes, R. E. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab306 · Cited by 75
Estebanez, A., Pascual, R., Gil, V., Ortiz, F., Santibáñez, M., & Barba, C. P. (2009) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0805-6 · Cited by 74
Rodríguez-Hernández, M. J., Cuberos, L., Pichardo, C., Caballero, F. J., Moreno, I., Jiménez-Mejías, M. E., García-Curiel, A., & Pachón, J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.479 · Cited by 74
Cho, S., Lee, D., Choi, S., Park, C., Chun, H., Park, Y.-J., Choi, J.-K., Lee, H.-J., Park, S. H., Choi, J., et al. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0801-7 · Cited by 74
Demırdal, T., Sarı, Ü. S., & Nemli, S. A. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0123-7 · Cited by 74
YILMAZ, G. R., Güven, T., Güner, R., Tufan, Z. K., İzdeş, Ş., Tasyaran, M. A., & Açıkgöz, Z. C. (2015) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.6195 · Cited by 72
Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa
J. Wolter, D., & D. Lister, P. (2013) · Current Pharmaceutical Design · doi:10.2174/138161213804070311 · Cited by 72
Park, H. J., Cho, J. H., Kim, H. J., Han, S. H., Jeong, S. H., & Byun, M. K. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.11.016 · Cited by 72
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance
Tamma, P. D., Beisken, S., Bergman, Y., Posch, A. E., Avdic, E., Sharara, S. L., Cosgrove, S. E., & Simner, P. J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1306 · Cited by 72
Self-citationRisk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia
Jeon, Y. D., Jeong, W., Kim, M. H., Jung, I. Y., Ahn, M. Y., Ann, H. W., Ahn, J. Y., Han, S. H., Choi, J. Y., Song, Y. G., et al. (2016) · Medicine · doi:10.1097/md.0000000000004375 · Cited by 71
Pfaller, M. A., Huband, M. D., Shortridge, D., & Flamm, R. K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02327-17 · Cited by 71
Periasamy, H., Joshi, P., Palwe, S. R., Shrivastava, R., Bhagwat, S., & Patel, M. V. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa021 · Cited by 71
Luna, B. M., Trebosc, V., Lee, B., Bakowski, M. A., Ulhaq, A., Yan, J., Lu, P., Cheng, J., Nielsen, T. B., Lim, J., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0737-6 · Cited by 71
Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
PASCALE, G. D., Lisi, L., Ciotti, G. M. P., Vallecoccia, M. S., Cutuli, S. L., Cascarano, L., Gelormini, C., Bello, G., Montini, L. M., Carelli, S., et al. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00715-2 · Cited by 71
Sánchez, M. B., & Martínez, J. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00714-15 · Cited by 70
Wang, R., Cosgrove, S. E., Tschudin‐Sutter, S., Han, J., Turnbull, A. E., Hsu, A. J., Avdic, E., Carroll, K. C., & Tamma, P. D. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw132 · Cited by 70
Self-citationBassetti, M., Vena, A., Giacobbe, D. R., Falcone, M., Tiseo, G., Giannella, M., Pascale, R., Meschiari, M., Digaetano, M., Oliva, A., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa139 · Cited by 70
McLeod, S. M., Shapiro, A. B., Moussa, S. H., Johnstone, M. R., McLaughlin, R. E., DeJonge, B. L. M., & Miller, A. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01576-17 · Cited by 69
Aitken, S. L., Tarrand, J. J., Deshpande, L. M., Tverdek, F. P., Jones, A. L., Shelburne, S. A., Prince, R. A., Bhatti, M. M., Rolston, K. V. I., Jones, R. N., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw398 · Cited by 68
Self-citationSader, H. S., Castanheira, M., & Flamm, R. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02083-16 · Cited by 68
Risk factors for death from Stenotrophomonas maltophilia bacteremia
Osawa, K., Shigemura, K., Kitagawa, K., Tokimatsu, I., & Fujisawa, M. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.03.011 · Cited by 68
Karlowsky, J. A., Kazmierczak, K. M., Bouchillon, S. K., DeJonge, B. L. M., Stone, G. G., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02569-17 · Cited by 68
Rubio, A. M., Kline, E. G., Jones, C. E., Chen, L., Kreiswirth, B. N., Nguyen, M. H., Clancy, C. J., Cooper, V. S., Haidar, G., Tyne, D. V., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00084-21 · Cited by 67
Self-citationPetrella, S., Clermont, D., Casin, I., Jarlier, V., & Sougakoff, W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.8.2287-2298.2001 · Cited by 66
Szabó, D., Bonomo, R. A., Silveira, F. P., Pasculle, A. W., Baxter, C. M., Linden, P. K., Hujer, A. M., Hujer, K. M., Deeley, K. B., & Paterson, D. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5058-5064.2005 · Cited by 66
Self-citationAlsenani, T. A., Viviani, S. L., Kumar, V., Taracila, M. A., Bethel, C. R., Barnes, M. D., Papp‐Wallace, K. M., Shields, R. K., Nguyen, M. H., Clancy, C. J., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02414-21 · Cited by 66
Self-citationEvolution of β-lactamase-mediated cefiderocol resistance
Fröhlich, C., Sørum, V., Tokuriki, N., Johnsen, P. J., & Samuelsen, Ø. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac221 · Cited by 66
Hilty, M., Sendi, P., Seiffert, S. N., Droz, S., Perreten, V., Hujer, A. M., Bonomo, R. A., Mühlemann, K., & Endimiani, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.022 · Cited by 65
Self-citationMoskowitz, S. M., Garber, E., Chen, Y., Clock, S. A., Tabibi, S., Miller, A. K., Doctor, M., & Saiman, L. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq131 · Cited by 65
Castanheira, M., Doyle, T. B., Kantro, V., Mendes, R. E., & Shortridge, D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01951-19 · Cited by 65
Biagi, M. J., Tan, X., Wu, T.-S., Jurkovic, M., Vialichka, A., Meyer, K., Mendes, R. E., & Wenzler, E. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01603-19 · Cited by 65
Bernabeu‐Wittel, M., Pichardo, C., García-Curiel, A., Pachón-Ibáñez, M. E., Ibáñez-Martínez, J., Me, J.-M., & Pachón, J. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01095.x · Cited by 64
Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii
Tseng, Y., Wang, J., Wu, F. L., Chen, Y., Chie, W., & Chang, S. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.04.024 · Cited by 64
Goff, D. A., Bauer, K. A. A., & Mangino, J. E. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu593 · Cited by 64
Hobson, C. A., Bonacorsi, S., Fahd, M., Baruchel, A., Cointe, A., Poey, N., Jacquier, H., Doit, C., Monjault, A., Tenaillon, O., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02463-18 · Cited by 64
Pfaller, M. A., Huband, M. D., Shortridge, D., & Flamm, R. K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02488-19 · Cited by 64
Biagi, M. J., Vialichka, A., Jurkovic, M., Wu, T.-S., Shajee, A., Lee, M., Patel, S., Mendes, R. E., & Wenzler, E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00559-20 · Cited by 64
Shropshire, W. C., Aitken, S. L., Pifer, R., Kim, J., Bhatti, M. M., Li, X., Kalia, A., Galloway-Peña, J., Sahasrabhojane, P. V., Arias, C. A., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa447 · Cited by 64
Self-citationNaesens, R., Vlieghe, E., Verbrugghe, W., Jorens, P. G., & Ieven, M. M. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-317 · Cited by 63
Tato, M., García-Castillo, M., Bofarull, A. M., & Cantón, R. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.07.004 · Cited by 63
Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales
Simner, P. J., Beisken, S., Bergman, Y., Ante, M., Posch, A. E., & Tamma, P. D. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2021.0095 · Cited by 63
Self-citationClinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline
Falagas, M. E., Karageorgopoulos, D. E., & Dimοpoulos, G. (2009) · Current Drug Metabolism · doi:10.2174/138920009787048356 · Cited by 62
Fung-Tomc, J. C., Gradelski, E., Huczko, E., Dougherty, T. J., KESSLER, R. E., & BONNER, D. P. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1289 · Cited by 62
Cai, B., Tillotson, G., Benjumea, D., Callahan, P. M., & ECHOLS, R. M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa141 · Cited by 62
Shields, R. K., Stellfox, M. E., Kline, E. G., Samanta, P., & Tyne, D. V. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac097 · Cited by 62
Castanheira, M., Duncan, L. R., Mendes, R. E., Sader, H. S., & Shortridge, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02125-17 · Cited by 61
Sader, H. S., Flamm, R. K., Carvalhaes, C. G., & Castanheira, M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01587-18 · Cited by 61
Sagan, O., Yakubsevitch, R., Yanev, K. P., Fomkin, R. N., Stone, E., Hines, D. J., O’Donnell, J. P., Miller, A. A., Isaacs, R., & Srinivasan, S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01506-19 · Cited by 61
Biagi, M. J., Lamm, D., Meyer, K., Vialichka, A., Jurkovic, M., Patel, S., Mendes, R. E., Bulman, Z. P., & Wenzler, E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00297-20 · Cited by 61
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
“…(for which sulbactam is the active component against A. baumannii PBP3) is the current preferred backbone of therapy, with evidence of improved outcomes when used at a high dose (≥9 g per day of sulbactam) in combination with another active agent in mostly observational studies 180 .”
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat
Lei, T.-Y., Liao, B.-B., Yang, L.-R., Wang, Y., & Chen, X.-B. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127839 · Cited by 174
Kaye, K. S., Belley, A. C., Barth, P., Lahlou, O., Knechtle, P., Motta, P., & Vélicitat, P. (2022) · JAMA · doi:10.1001/jama.2022.17034 · Cited by 147
Carmeli, Y., Cisneros, J. M., Paul, M., Daikos, G. L., Wang, M., Torre‐Cisneros, J., Singer, G., Titov, I., Gumenchuk, I., Zhao, Y., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00499-7 · Cited by 146
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.